Gynoflor (Estriol, Lactobacillus Acidophilus)

Gynoflor is indicated for several gynecological conditions related to estrogen deficiency in post‑menopausal women.

• Relief of vulvovaginal atrophy, including thinning of the vaginal lining.
• Reduction of dyspareunia (painful intercourse) associated with menopause.
• Management of vaginal dryness and burning sensations.
• Alleviation of itching, irritation, and discomfort caused by low estrogen levels.
• Restoration of normal vaginal flora through the probiotic component.

Side effects of Gynoflor are generally mild because the estrogen is delivered locally, but some users may experience reactions.

Common

• Mild vaginal irritation or burning after insertion.
• Spotting or light vaginal bleeding.
• Increased vaginal discharge that is clear or whitish.
• Temporary abdominal cramping or pelvic discomfort.

Serious

• Signs of estrogen‑dependent cancer such as abnormal vaginal bleeding.
• Severe allergic reaction with swelling, rash, or difficulty breathing.
• Persistent headache or visual disturbances.
• Thromboembolic events (rare) such as leg pain or swelling.

Before prescribing Gynoflor, clinicians should evaluate patient history and consider specific safety warnings.

• Not recommended for women with known estrogen‑sensitive cancers (e.g., breast, endometrial).
• Use with caution in patients with a history of thromboembolic disorders.
• Avoid in active vaginal infections until they are adequately treated.
• Do not use during pregnancy or lactation unless clearly indicated by a physician.
• Monitor for signs of abnormal uterine bleeding during therapy.
• Assess renal or hepatic impairment, as it may affect drug metabolism.

Gynoflor may interact with other medications or substances that influence estrogen activity or vaginal environment.

Avoid

• Systemic hormone replacement therapy or oral contraceptives containing estrogen, which could increase overall estrogen exposure.
• Antifungal or antibacterial vaginal products applied simultaneously, as they may reduce probiotic viability.

Use with caution

• Anticoagulants (e.g., warfarin) because estrogen can affect clotting factors.
• Selective estrogen receptor modulators (SERMs) that alter estrogen pathways.
• Certain antihypertensive agents that may be affected by fluid shifts in the vaginal mucosa.